Drug pricing should depend on shared values
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Nature 552, S78 (2017)
This article is part of Nature Outlook: Cancer immunotherapy, an editorially independent supplement produced with the financial support of third parties. About this content.
Rahib, L. et al. Cancer Res. 74, 2913–2921 (2014).
Institute for Clinical and Economic Review. Treatment Options for Advanced Non-Small Cell Lung Cancer: Effectiveness, Value and Value-Based Price Benchmarks; available at: http://go.nature.com/2yyalic
Carlson, J. J., Sullivan, S. D., Garrison, L. P., Neumann, P. J. & Veenstra, D. L. Health Policy 96, 179–190 (2010).
S.R. is a consultant at Bayer, Genentech, BMS and Kite Pharma, and has received research grants from the Personalized Medicine Coalition.